Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Improved survival seen with structured program in patients with resected colon cancer who have completed adjuvant chemo.

Both hand cooling and hand compression reduced the incidence of grade 2 or higher chemotherapy-induced peripheral neuropathy ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 2 Translational Data Presented at ESMO On June 18, 2025, ...

Physical activity for cancer survivors supported by recent research; CAPABLE helps cancer survivors find their physical ...